TY - JOUR
T1 - Disulfiram maintenance employee alcoholism treatment
T2 - A three-phase evaluation
AU - Robichaud, Colleen
AU - Strickler, Daniel
AU - Bigelow, George
AU - Liebson, Ira
N1 - Funding Information:
Summary-Absenteeism rates of industrial employees (IV = 21) referred by their employers to alcoholism treatment were evaluated during three phases: pretreatment (the 24 months immediately prior to treatment); treatment (the period of continuous treatment enrolment. averaging IO.6 months): and post-treatment (the period immediately following treatment. averaging 4.4 months). Treatment consisted of disuihrsm maintenance-routine supervised ingestion of disuihr-am--without schedukd counseling. The median per cent of scheduled uork days absent for each phase was: prr-treatment, 9.87;: treatment. 1.77;: post-treatment. 6.?*b. Absenteeism during the treatment phase was significantly iess (p < 0.01) than that during pre-treatment and post-treatment, which did not differ significantly from one anather. The five-fold reduction in absenteeism was specifically related to treatment delivery. and appears superior to the two-fold reduction reported for traditional employee alcoholism treatment via counseling The workplace is thought to provide a uniquely potent context within v&i& to treat alcoholism. Employer-initiated treatment for employees with an akohoi-related problem usually consists of referral for alcoholism counseling or for Alcoholics Anonymous participation. Traditional programs of this type typically find a * Supported by USPHS research grant AA-00179 and by Research Scientist Development Award DA-00050. This research was reviewed and approved by the Institutional Review Board [or Human Research at Baltimore City Hospitats. Send reprint requests to George Bigelow. Department of Psychiatry, Baltimore City Hospitals, Baitimore. MD 711%. U.S.A.
PY - 1979
Y1 - 1979
N2 - Absenteeism rates of industrial employees (N = 21) referred by their employers to alcoholism treatment were evaluated during three phases: pre-treatment (the 24 months immediately prior to treatment); treatment (the period of continuous treatment enrolment, averaging 10.6 months); and post-treatment (the period immediately following treatment, averaging 4.4 months). Treatment consisted of disulfiram maintenance-routine supervised ingestion of disulfiram-without scheduled counseling. The median per cent of scheduled work days absent for each phase was: pre-treatment, 9.8%; treatment, 1.7%; post-treatment, 6.7%. Absenteeism during the treatment phase was significantly less (p < 0.01) than that during pre-treatment and post-treatment, which did not differ significantly from one another. The five-fold reduction in absenteeism was specifically related to treatment delivery, and appears superior to the two-fold reduction reported for traditional employee alcoholism treatment via counseling.
AB - Absenteeism rates of industrial employees (N = 21) referred by their employers to alcoholism treatment were evaluated during three phases: pre-treatment (the 24 months immediately prior to treatment); treatment (the period of continuous treatment enrolment, averaging 10.6 months); and post-treatment (the period immediately following treatment, averaging 4.4 months). Treatment consisted of disulfiram maintenance-routine supervised ingestion of disulfiram-without scheduled counseling. The median per cent of scheduled work days absent for each phase was: pre-treatment, 9.8%; treatment, 1.7%; post-treatment, 6.7%. Absenteeism during the treatment phase was significantly less (p < 0.01) than that during pre-treatment and post-treatment, which did not differ significantly from one another. The five-fold reduction in absenteeism was specifically related to treatment delivery, and appears superior to the two-fold reduction reported for traditional employee alcoholism treatment via counseling.
UR - http://www.scopus.com/inward/record.url?scp=0018577988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018577988&partnerID=8YFLogxK
U2 - 10.1016/0005-7967(79)90107-4
DO - 10.1016/0005-7967(79)90107-4
M3 - Article
C2 - 526252
AN - SCOPUS:0018577988
SN - 0005-7967
VL - 17
SP - 618
EP - 621
JO - Behaviour Research and Therapy
JF - Behaviour Research and Therapy
IS - 6
ER -